The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer

BACKGROUND: Pancreatic cancer is a lethal malignancy that frequently acquires resistance to conventional chemotherapies often associated with overexpression of inhibitors of apoptosis proteins (IAPs). We have recently described a novel means to deliver second mitochondria-derived activator of caspas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Hashim, Yassar M., Vangveravong, Suwanna, Sankpal, Narendra V., Binder, Pratibha S., Liu, Jingxia, Goedegebuure, S. Peter, Mach, Robert H., Spitzer, Dirk, Hawkins, William G.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5240213/
https://ncbi.nlm.nih.gov/pubmed/28095907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0470-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars